Difference between revisions of "Part:BBa K2926081"
(2 intermediate revisions by the same user not shown) | |||
Line 34: | Line 34: | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<div class="dark"> | <div class="dark"> | ||
+ | </div> | ||
<!-- <div class="contentBlock"> | <!-- <div class="contentBlock"> | ||
Line 53: | Line 48: | ||
<div class="contentBlock"> | <div class="contentBlock"> | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<!--</div>--> | <!--</div>--> | ||
Latest revision as of 03:59, 22 October 2019
Ampicillin resistance protein Part 2
fdhg
Antibiotic and Resistances
Ampicillin
Another antibiotic used to prevent bacterial infections poses ampicillin. Similar to other antibiotics, it can be administrated via mouth and injection into a muscle. It is classified under the category of bacteriolytic antibiotics and can penetrate gram-positive and gram-negative bacteria. It is responsible for the inhibition of transpeptidase, that is responsible for the cell wall of the bacteria by inhibiting the final cell wall synthesis in binary fission (Ampicillin Monograph for Professionals, 2018)
Resistance Ampicillin
Beta-lactamases are enzymes that bacteria produce to defend themselves against β-lactam antibiotics. The most common lactamases are the class A enzymes, such as the clinically significant TEM-1 lactamase. (Waley, 1992). It provides antibiotic resistance by breaking the antibiotics structure. All these antibiotics all have a common element in their molecular structure: a four-atom ring known as a β-lactam. Through hydrolysis, the enzyme breaks the β-lactam ring open, deactivating the molecule's antibacterial properties.
Chloramphenicol
A commonly used antibiotic for bacterial infections is chloramphenicol (Chloramphenicol Monograph for Professionals, 2019). It was isolated from Streptomyces venezuelae in 1947 and was the first artificially produced antibiotic (Pongs O.,1979). Once it passes the cell membrane it has a bacteriolytic effect. It binds to specific residues of the 23S rRNA of the 50S ribosomal subunit, that hampers the substrate binding in the ribosome (Chloramphenicol - Infectious Diseases, 2019) (Wolfe, A. D., 1965). Chloramphenicol is often one of the ingredients in eye ointments for the treatment of conjunctivitis (Edwards 2009). In some other cases it can be administered by mouth or vein injection (Rosenfield, Logan, & Edwards, 2009). Furthermore, it is used to treat hazardous bacterial infections like plaque, cholera, MRSA or typhoid fever (Ingebrigtsen 2017).
Resistance Chloramphenicol
Chloramphenicol Acetyltransferase (CAT) is an enzyme originally identified in Escherichia coli that mediates resistance to chloramphenicol (Figure 3). (Shaw 1983). Three types of this enzyme are known and catalyse the same reaction, CATI, CATII and CATIII. The genomic analysis of the different CAT types shows that the boundaries between them are not completely clear, however type III is best characterised. Since the iGEM community uses commonly type I, as in part BBa_J31005 and in the standard backbone pSB1C3, we decided to do the same.
CAT is an enzyme originally identified in Escherichia coli that mediates resistance to chloramphenicol (Shaw 1983). It covalently attaches an acetyl group from acetyl-CoA to chloramphenicol, hence chloramphenicol is unable to bind to the 23S rRNA (Shaw 1991) (Figure 4)
Hygromycin B
Hygromycin B is an aminoglycoside that can kill prokaryotic and eukaryotic cells. It was developed in 1950 and used for animals as an anti-worming agent. This antibiotic is produced by Streptomyces hygroscopicus and later in 1980 the resistance gene was discovered (Gritz & Davies, 1983; Kaster, Burgett, Rao, & Ingolia, 1983). The mechanism of hygromycin B is to inhibit the enzymic translocation of peptidyl-tRNA and thus blocking the cytoplasmic protein synthesis (González, Jiménez, Vázquez, Davies, & Schindler, 1978).
Resistance Hygromycin B
One of the enzymes that mediates resistance against hygromycin B (hygB) is called hygromycin-B 4-O-kinase and was found in E. coli (Hph—Hygromycin-B 4-O-kinase, Uniprot). It has two substrates, both ATP and Hygromycin B. It inactivates the antibiotic through phosphorilation, so that it has as products phospho-hygromycin B and ADP (Figure ). The same enzyme with the same characteristics, but from the organism Streptomyces fradiae named APH(4)-Ia, was tested for numerous aminoglycoside antibiotics, that perform possible substrates (Stogios et. al., 2011). The substrates that were tested included 4,6-disubstituted 2-deoxystreptamine-based, 4,5-disubstituted 2-deoxystreptamine-based and atypical aminoglycosides. The only antibiotic that was susceptible for phosphorylation by APH(4)-Ia was hygB. Such a specificity is not common for APHs in generall (Stogios et. al., 2011).
Kanamycin
Kanamycin is a glycoside that was first isolated in 1957 from the bacterium Streptomyces Kanamycericus (Sneader, 2005). It is used to treat bacterial infections and tuberculosis (‘Kantrex—FDA prescribing information, side effects and uses’, n.d.) and can be taken up by mouth, injection into a vein or into a muscle, but is ineffective against viral infections. The mechanism how kanamycin inhibit cell growth is by binding to the 30S subunit of the bacterial ribosome. This leads to incorrect alignment with the mRNA and therefore to the assembly of a false amino acid sequence. That leads to the assembly of on functional peptide chains (‘Kanamycin’, n.d.).
Resistance Kanamycin
Aminoglycoside-3'-phosphotransferase (APH(3')), also known as aminoglycoside kinase, is an enzyme that primarily catalyses the reaction of adding a phosphate from ATP to the 3'-hydroxyl group of a 4,6-disubstituted aminoglycoside (Figure 4)(Frontiers in Bioscience 4, d9-21, 1999). In this case kanamycin. More specific we used aph(3’)-Ia. It provides resistance against kanamycin as well as neomycin and pradimicin (Shaw, 1993).
Intein-Mediated Protein Splicing
Inteins
An intein is a segment of a precursor protein which is able to mediate its own excision form the precursor protein, while joining the flanking protein sequences together, creating a new peptide bond.
The intein-mediated protein splicing occurs after the mRNA is translated into a sequence of amino acids. Prior to the splicing process the N-terminal part of the precursor protein is called N-extein, the center part is the intein and the C-terminal part is named C-extein. The spliced protein is called an extein as well.
The intein-mediated protein splicing occurs after the mRNA is translated into a sequence of amino acids. Prior to the splicing process the N-terminal part of the precursor protein is called N-extein, the center part is the intein and the C-terminal part is named C-extein. The spliced protein is called an extein as well.
Split Inteins
A very special but small subset of inteins are the so-called split-inteins. They are transcribed and translated as separate polypeptides but rapidly associate afterwards to from the active intein. The active intein then ligates the fused N- and C-exteins in a process called protein trans-splicing.
After the first split intein SspDnaE, a subunit of the DNA polymerase III (DnaE) from Synechocystis sp. strain PCC6803 was discovered. Several homologous inteins were identified in cyanobacteria. (Wei et al. 2006, Dassa et al. 2007) However apart from sequence analysis there have only been few attempts to further characterize or compare their splicing efficiencies (Dassa et al. 2007). Nevertheless a split intein from the cyanobacterium Nostoc punctiforme (NpuDnaE) which is highly homologous to Ssp DnaE was analyzed quite extensively. It has shown higher activities than SspDnaE in vivo and in vitro (Iwai et al. 2006; Zettler et al. 2009). Additionally it has a boarder range of acceptance when it comes to the residues at the end of the C-extein (Iwai et al. 2006).
Mechanism
Split-Resistance Genes
The selection marker is split in two halfs. Each part of it is cloned into a different vector carrying distinct cassettes (Figure 4). The marekers N-terminal (MarN) and C-terminal (MarC) fragment is fused downstream and upstream respectively with the N-terminal (IntN) and C-terminal (IntC) fragment of the split Npu DnaE Intein. Only cells that contain both plasmids can grow on hygromycin rich medium. This occurs due to the intein fragments, because after the fusions being separately expressed, the split intein sections find one another and through trans splicing cut themselves out and fuse their flanking sites via peptide bond. Thereby an intact hygromycin-B 4-O-kinase is released and the cells gain the selection ability.
Fusion-Protein Structure
There are many important features, that must be taken into consideration while planning to construct a two-plasmid system with split antibiotics. Otherwise the probability of success decreases. While trying to find the right position to split the resistance gene it must be searched for the right N- and C-terminal extein sequences. In our case we talked to Mr. Albert Cheng, PhD who suggested us to orientate ourselves on Table 1 (Cheriyan, 2013). On this table the relative favourability of each amino acid at each relevant position neighbouring the inteins is documented. Additionally, it is important to make sure that the split point is not interrupting an important secondary structure of the protein and that the exteins are not hydrophobic. Thanks to Dr Francine Perler reminding us about the hydrophobicity of the exteins, we did not forget to take it into consideration. Instead of analysing ourselves the DNA sequence of the resistance genes we decided to do a model, that will be able to output the right split points.
As a positive reference to our selected split points we contacted Prof. Dr. Barbara Di Ventura. She provided us with the plasmids that contain the protein fusions, so that we can use them to clone our new backbones. Two plasmids encoding an active TEM-1 lactamase for ampicillin resistance and other two plasmids encoding the aph(3’)-Ia for kanamycin resistance (not published jet, Navaneethan Palanisam, Freiburg University).
As a positive reference to our selected split points we contacted Prof. Dr. Barbara Di Ventura. She provided us with the plasmids that contain the protein fusions, so that we can use them to clone our new backbones. Two plasmids encoding an active TEM-1 lactamase for ampicillin resistance and other two plasmids encoding the aph(3’)-Ia for kanamycin resistance (not published jet, Navaneethan Palanisam, Freiburg University).
Amino Acid | rF at the N-terminal extein | rF at the C-terminal extein | ||||
---|---|---|---|---|---|---|
-3 | -2 | -1 | +1 | +2 | +3 | |
D | 1.39 | 1.52 | 0.00 | 0.00 | 0.00 | 1.26 |
E | 1.26 | 3.51 | 0.07 | 0.00 | 0.00 | 5.5 |
N | 0.93 | 1.26 | 2.19 | 0.00 | 0.00 | 8.61 |
Q | 1.39 | 0.86 | 0.33 | 0.00 | 0.00 | 0.27 |
H | 1.06 | 1.26 | 2.19 | 0.00 | 0.00 | 8.61 |
K | 1.59 | 0.93 | 4.44 | 0.00 | 0.07 | 0.00 |
R | 1.81 | 0.2 | 0.86 | 0.00 | 0.00 | 0.00 |
S | 0.99 | 1.24 | 1.37 | 0.00 | 0.00 | 0.07 |
C | 0.46 | 0.40 | 0.80 | 50 | 0.07 | 0.07 |
T | 0.63 | 0.89 | 1.59 | 0.00 | 0.00 | 0.96 |
P | 0.80 | 1.52 | 0.00 | 0.00 | 0.00 | 0.00 |
G | 4.67 | 2.68 | 0.17 | 0.00 | 0.00 | 0.03 |
A | 0.63 | 0.83 | 1.92 | 0.00 | 0.00 | 0.00 |
V | 0.56 | 0.50 | 0.23 | 0.00 | 0.03 | 0.10 |
I | 0.07 | 0.53 | 0.00 | 0.00 | 0.00 | 0.40 |
L | 0.11 | 0.57 | 0.75 | 0.00 | 0.00 | 0.82 |
M | 0.13 | 0.73 | 1.26 | 20 | 0.07 | 2.25 |
F | 0.13 | 0.73 | 1.26 | 0.00 | 0.07 | 2.25 |
Y | 0.20 | 0.60 | 2.05 | 0.00 | 0.13 | 5.23 |
W | 0.07 | 0.40 | 0.99 | 0.00 | 29.42 | 0.07 |
Characterization
Single Plasmid Control
An important aspect, when constructing and working with a split-resistance gene system is to make sure, that one plasmid does not provide to the cells the ability to grow on medium with the corresponding antibiotic. Therefore, from every cell collection containing one of the plasmid pairs, we plated different on plates with low antibiotic concentration.
Normal working concentrations for chloramphenicol are between 25 and 170 µg/mL (ATCC_recommendations_antibiotic_concentrations, 2003). As Figure 11 shows the chloramphenicol plate was divided into four segments. Cells were plated on the upper left site containing pSB1Ca3, upper right site containing pSB1Cc3, lower left site containing pSB3Cb5 and on the lower right site containing pSB3Cd5. On none of the segments growing colonies can be seen and that proves, that only one plasmid does not provide antibiotic resistance. Similar is the case with hygromycin.
Normal working concentrations for hygromycin B is between 200 and 500 µg/mL (Hygromycin B, Thermofisher). As Figure 12 shows the hygromycin plate was divided into two segments. Cells were plated on the upper site containing pSB1Ha3 and on the lower site containing pSB3Hb5. Like before, none of the plated colonies grew.
Normal working concentrations for chloramphenicol are between 25 and 170 µg/mL (ATCC_recommendations_antibiotic_concentrations, 2003). As Figure 11 shows the chloramphenicol plate was divided into four segments. Cells were plated on the upper left site containing pSB1Ca3, upper right site containing pSB1Cc3, lower left site containing pSB3Cb5 and on the lower right site containing pSB3Cd5. On none of the segments growing colonies can be seen and that proves, that only one plasmid does not provide antibiotic resistance. Similar is the case with hygromycin.
Normal working concentrations for hygromycin B is between 200 and 500 µg/mL (Hygromycin B, Thermofisher). As Figure 12 shows the hygromycin plate was divided into two segments. Cells were plated on the upper site containing pSB1Ha3 and on the lower site containing pSB3Hb5. Like before, none of the plated colonies grew.
Growth Control
After proving that one plasmid does not provide an antibiotic resistance, the next experiment was to analyse the growth efficiency of the double-plasmid containing cells. Therefore, we poured plates with diverse concentrations of chloramphenicol and hygromycin B (Figure 13, 14).
Regarding the chloramphenicol resistance the concentrations that were prepared are from the upper left to the lower right site 0.1, 1, 7, 10, 20, 40, 60, 80, 100 μg/mL. Each plate was divided into three sections. On the upper left site, DH5α was plated as the negative control, on the upper right site the colonies containing both plasmids and on the lower site a colony containing pSB1C3 (link) gene. The maximal chloramphenicol concentration on which DH5α grows is 0.1 μg/mL. The section for the split-marker was additionally divided into two segments, for the two different split point of chloramphenicol. On the left part the CmA version and on the right part the CmB version was plated. Until a concentration of 1 µg/mL and in other two repeats till a concentration of 5 µg/mL the two split system versions were providing the cell resistance against chloramphenicol. Furthermore, it can be observed from the figure that the CmB version works better than the other one. This was to assume, because of the extein sequence flanking the split Npu DnaE intein.
For the hygromycin B resistance the concentrations that were prepared are from the upper left to the lower right site 30, 40, 60 80, 100, 200, 500 and 1000 μg/mL. Each plate was divided into three sections. On the upper left site, DH5α was plated as the negative control, on the upper right site the colonies containing both plasmids and on the lower site a colony containing plasmid with a hygromycin resistance gene. For DH5α the used concentrations were too high to grow. The positive control did not have any problems growing on hygromycin B. The cells with the split antibiotic resistance plasmids easily grew on the plates till a concentration of 500 μg/mL and with some difficulties on 1000 μg/mL.
Regarding the chloramphenicol resistance the concentrations that were prepared are from the upper left to the lower right site 0.1, 1, 7, 10, 20, 40, 60, 80, 100 μg/mL. Each plate was divided into three sections. On the upper left site, DH5α was plated as the negative control, on the upper right site the colonies containing both plasmids and on the lower site a colony containing pSB1C3 (link) gene. The maximal chloramphenicol concentration on which DH5α grows is 0.1 μg/mL. The section for the split-marker was additionally divided into two segments, for the two different split point of chloramphenicol. On the left part the CmA version and on the right part the CmB version was plated. Until a concentration of 1 µg/mL and in other two repeats till a concentration of 5 µg/mL the two split system versions were providing the cell resistance against chloramphenicol. Furthermore, it can be observed from the figure that the CmB version works better than the other one. This was to assume, because of the extein sequence flanking the split Npu DnaE intein.
Regarding the ampicillin resistance the concentrations that were prepared are from the upper left to the lower right site 5, 30, 60, 80, 90, 100, 150, 200 and 300 μg/mL (Fig.16). The plate was divided into three sections. On the upper left site, DH5α was plated as the negative control, on the upper right site the colonies containing both plasmids and on the lower site a colony containing pTXB1. DH5α could not grow on any of these concentrations. The positive control was also able to grow on any ampicillin concentration. The cells with the split antibiotic resistance plasmids easily grew on the plates till a concentration of 200 μg/mL.
For the kanamycin resistance the concentrations that were prepared are from the upper left to the lower right site 35, 40, 45, 50, 60, 70, 80 and 90μg/mL (Fig.17). As before too, the plate was divided into three sections. On the upper left site, DH5α was plated as the negative control, on the upper right site the colonies containing both plasmids and on the lower site a colony containing pSB1K3. For DH5α the used concentrations were too high to grow, except of the 40µg/ml plate, where two colonies can be seen. The positive control was also able to grow on any ampicillin concentration. The cells with the split antibiotic resistance plasmids easily grew on the plates till a concentration of 90 μg/mL.
Growth Control in LB-Medium
In order to test the functionality of our split resistance genes, we conducted growth experiments with DH5α containing the two-plasmid system. The Escherichia colis (E. colis) were cultivated in liquid LB media and all tested plasmids were transformed in DH5α. For every growth curve there were five samples. For the split kanamycin curve the first sample was DH5α cultivated in LB-media without antibiotic, the second DH5α in LB-kanamycin, the third DH5α + pSB1K3 in LB-kanamycin, the fourth DH5α + pSB1C3 + pSB3T5 in LB-kanamycin-tetracyclin, the fifth DH5α + pSB1Ka3 + pSB3Kb5 in LB-kanamycin.
DH5α with antibiotic did not grow in comparison to DH5α without antibiotic that showed the expected curve. The cells containing pSB1K3 grew the best and the split antibiotic system followed . It could also be observed, that the cells containing two plasmids with each one antibiotic resistance did grow less efficient than the split kanamycin cells.
DH5α with antibiotic did not grow in comparison to DH5α without antibiotic that showed the expected curve. The cells containing pSB1K3 grew the best and the split antibiotic system followed . It could also be observed, that the cells containing two plasmids with each one antibiotic resistance did grow less efficient than the split kanamycin cells.
The same procedure was conducted to test the functionality of the split ampicillin system. The Escherichia colis (E. colis) were also cultivated in liquid LB media and all tested plasmids were transformed in DH5α. The first sample was DH5α cultivated in LB-media without antibiotic, the second DH5α in LB-kanamycin, the third DH5α + pTXB1 in LB-ampicillin, the fourth DH5α + pSB1C3 + pSB3T5 in LB-chloramphenicol-tetracyclin, the fifth DH5α + pSB1Aa3 + pSB3Ab5 also in LB-ampicillin.
DH5α with antibiotic did not grow in comparison to DH5α without antibiotic, as also seen before. The cells containing pSB1K3 grew as good as the cells with the split antibiotic system. DH5α with two antibiotic resistance genes did grow better than DH5α with antibiotic, but worser than the others.
DH5α with antibiotic did not grow in comparison to DH5α without antibiotic, as also seen before. The cells containing pSB1K3 grew as good as the cells with the split antibiotic system. DH5α with two antibiotic resistance genes did grow better than DH5α with antibiotic, but worser than the others.
Modeling Split Chloramphenicol Resistance
We aimed to split the protein conveying resistance to chloramphenicol, chloramphenicol acetyltransferase (BBa_J3105). The resistance protein is commonly used within iGEM, thus making a split Chloramphenicol acetyltransferasa a vluable addition to the iGEM partsreg. The protein sequence of this part can be found here.
According to our modeling, the best split point to use when introducing Npu DnaE was VAQ-CTY in the positions 28-33, the B(VAQCTY) is 56.95.
Even though this split point is located at the second amino acid of a beta-sheet, we decided to test whether splitting at this position could lead to Chloramphenicol acetyltransferase fragments that could be reconstituted by intein-mediated protein splicing.
Similar to our modeling of the split kanamycin resistance, we used the homology modeling software MODELLER (Sali & Webb, 1989) to visualize each part of the chloramphenicol acetyltransferase fused to the Npu DnaE intein.
Even though this split point is located at the second amino acid of a beta-sheet, we decided to test whether splitting at this position could lead to Chloramphenicol acetyltransferase fragments that could be reconstituted by intein-mediated protein splicing.
Similar to our modeling of the split kanamycin resistance, we used the homology modeling software MODELLER (Sali & Webb, 1989) to visualize each part of the chloramphenicol acetyltransferase fused to the Npu DnaE intein.
The amino acid sequences given to the software were:
Part 1:
MEKKITGYTTVDISQWHRKEHFEAFQSVAQCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNNLEGHHHHHH
Part 2:
MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCCTYNQTVQLDITAFLKTVKKNKHKFYPAFIHILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIYSQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA
MEKKITGYTTVDISQWHRKEHFEAFQSVAQCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNNLEGHHHHHH
Part 2:
MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCCTYNQTVQLDITAFLKTVKKNKHKFYPAFIHILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIYSQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA
The templates used for homology modeling were:
Part 1 | Part 2 |
---|---|
1NOC, chain B (Chloramphenicol acetyltransferase) | 1NOC, chain B (Chloramphenicol acetyltransferase) |
4QFQ, chain A (Npu DnaE) | 4QFQ, chain B (Npu DnaE) |
5OL6, chain A (inactivated Npu SICLOPPS intein with CAFHPQ extein) | 5OL6, chain B (inactivated Npu SICLOPPS intein with CAFHPQ extein) |
4KL5, chain A (Npu DnaE) | 1QCA, chain A (Type III Chloramphenicol acetyltransferase) |
2KEQ, chain A (DnaE intein from Nostoc punctiforme) | 3CLA, chain A (Type III Chloramphenicosl acetyltransferase) |
As shown in growth experiments on plates (Fig. 9), implementing split antibiotic resistances is feasible. Using the split points predicted with the model allowed us to successfully construct functional split antibiotic resistances.
The templates used for homology modeling were:
After running the MODELLER software (Sali & Webb, 1989), two protein structures were calculated and placed adjacent to each other using Chimera (Pettersen et al., 2004).
Modeling Split Kanamycin Resistance
We aimed to split the protein conveying resistance to chloramphenicol, chloramphenicol acetyltransferase (BBa_J3105). The resistance protein is commonly used within iGEM, thus making a split Chloramphenicol acetyltransferasa a vluable addition to the iGEM partsreg. The protein sequence of this part can be found here.
According to our modeling, the best split point to use when introducing Npu DnaE was VAQ-CTY in the positions 28-33, the B(VAQCTY) is 56.95.
Even though this split point is located at the second amino acid of a beta-sheet, we decided to test whether splitting at this position could lead to Chloramphenicol acetyltransferase fragments that could be reconstituted by intein-mediated protein splicing.
Similar to our modeling of the split kanamycin resistance, we used the homology modeling software MODELLER (Sali & Webb, 1989) to visualize each part of the chloramphenicol acetyltransferase fused to the Npu DnaE intein.
Even though this split point is located at the second amino acid of a beta-sheet, we decided to test whether splitting at this position could lead to Chloramphenicol acetyltransferase fragments that could be reconstituted by intein-mediated protein splicing.
Similar to our modeling of the split kanamycin resistance, we used the homology modeling software MODELLER (Sali & Webb, 1989) to visualize each part of the chloramphenicol acetyltransferase fused to the Npu DnaE intein.
The amino acid sequences given to the software were:
Part 1:
MEKKITGYTTVDISQWHRKEHFEAFQSVAQCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNNLEGHHHHHH
Part 2:
MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCCTYNQTVQLDITAFLKTVKKNKHKFYPAFIHILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIYSQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA
MEKKITGYTTVDISQWHRKEHFEAFQSVAQCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNNLEGHHHHHH
Part 2:
MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCCTYNQTVQLDITAFLKTVKKNKHKFYPAFIHILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIYSQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA
The templates used for homology modeling were:
Part 1 | Part 2 |
---|---|
1NOC, chain B (Chloramphenicol acetyltransferase) | 1NOC, chain B (Chloramphenicol acetyltransferase) |
4QFQ, chain A (Npu DnaE) | 4QFQ, chain B (Npu DnaE) |
5OL6, chain A (inactivated Npu SICLOPPS intein with CAFHPQ extein) | 5OL6, chain B (inactivated Npu SICLOPPS intein with CAFHPQ extein) |
4KL5, chain A (Npu DnaE) | 1QCA, chain A (Type III Chloramphenicol acetyltransferase) |
2KEQ, chain A (DnaE intein from Nostoc punctiforme) | 3CLA, chain A (Type III Chloramphenicosl acetyltransferase) |
As shown in growth experiments on plates (Fig. 9), implementing split antibiotic resistances is feasible. Using the split points predicted with the model allowed us to successfully construct functional split antibiotic resistances.
Collection
Split versions | Part 1 | Part 1 Composition | Part 2 | Part 2 Composition |
---|---|---|---|---|
Split CmA | pSB1Ca3 | split NpuC intein, CmR A spit 2 and the insert TcR | pSB3Cb5 | CmR A spit 1, split NpuN intein and the insert KanR |
Split CmB | pSB1Cc3 | split NpuC intein, CmR B spit 2 and the insert TcR | pSB3Cd5 | CmR B spit 1, split NpuN intein and the insert KanR |
Split Hyg | pSB1Ha3 | HygR spit 1, split NpuN intein and the insert TcR | pSB3Hb5 | split NpuC intein, HygR spit 2 and the insert KanR | Split Kan | pSB1Ka3 | KanR spit 1, split N-terminal intein and the insert TcR | pSB3Kb5 | split C-terminal intein, KanR spit 2 and the insert CmR | Split Amp | pSB1Aa3 | split C-terminal intein, AmpR spit 2 and the insert TcR | pSB3Ab5 | AmpR spit 1, split N-terminal intein and the insert KanR |
References
Quelle 1
Quelle 2
Quelle 3
Quelle 4
Quelle 5
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 524
Illegal SapI.rc site found at 28